Analysts See $-0.19 EPS for Affimed N.V. (AFMD)

March 21, 2018 - By Marguerite Chambers

 Analysts See $ 0.19 EPS for Affimed N.V. (AFMD)

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.19 EPS on March, 29.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.21 EPS previously, Affimed N.V.’s analysts see -9.52 % EPS growth. The stock increased 0.00% or $0.0001 during the last trading session, reaching $2.1001. About 9,295 shares traded. Affimed N.V. (NASDAQ:AFMD) has declined 19.09% since March 21, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. As per Friday, August 12, the company rating was downgraded by Leerink Swann. The rating was maintained by Jefferies on Thursday, May 19 with “Hold”. Wells Fargo initiated Affimed N.V. (NASDAQ:AFMD) on Friday, December 4 with “Outperform” rating. Zacks upgraded the stock to “Hold” rating in Thursday, September 3 report. The firm has “Hold” rating given on Monday, June 12 by Jefferies. The company was initiated on Tuesday, April 12 by BMO Capital Markets. The rating was maintained by Oppenheimer on Thursday, August 6 with “Outperform”. Leerink Swann downgraded the stock to “Market Perform” rating in Thursday, May 19 report. On Thursday, December 10 the stock rating was initiated by Laidlaw with “Buy”. The firm has “Hold” rating given on Thursday, August 31 by Jefferies.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $127.40 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: